# Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT00072709** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 551 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** TCH346

## Key facts

- **NCT ID:** NCT00072709
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2011-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072709, "Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00072709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*